Available Technology

Stable Cell Line for Enhanced Expression and Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2 (TIMP-2)

Studies have shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) suppresses tumor growth and tumor-associated angiogenesis. Currently, the main obstacle in using TIMP-2 as a biologic therapeutic has been the inability to produce sufficient quantities of the protein for testing and development.

NCIRadiation Oncology Branch(ROB) researchers have developed a unique HEK-293F cell line that stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases. Importantly, this inventive cell line can also be produced in great quantities using good laboratory practice (GLP) manufacturing.

Benefits 
This is the first time TIMP-2 can be produced in quantities sufficient for testing and development as a novel biologic therapeutic for the treatment of cancer, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.
Inventors: 

Beiyang Wei

Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin